Plasticity of 150-Loop in Influenza Neuraminidase Explored by Hamiltonian Replica Exchange Molecular Dynamics Simulations

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Han, Nanyu ^a   Mu, Yuguang ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS SIALIDASE;

ALGORITHM; ARTICLE; CALCULATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; HAMILTONIAN REPLICA EXCHANGE MOLECULAR DYNAMICS SIMULATION; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA VIRUS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PANDEMIC INFLUENZA; PLASTICITY; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN MOTIF; SIMULATION;

CLUSTER ANALYSIS; INFLUENZA A VIRUS; MOLECULAR DYNAMICS SIMULATION; NEURAMINIDASE; PROTEIN CONFORMATION;

ORTHOMYXOVIRIDAE;

EID: 84876041941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060995     Document Type: Article

References (41)

1. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y, (1992) Evolution and Ecology of Influenza-a Viruses. Microbiol Rev 56: 152-179.
2. Webby RJ, Webster RG, (2003) Are we ready for pandemic influenza? Science 302: 1519-1522.
3. Fauci AS, (2006) Pandemic influenza threat and preparedness. Emerg Infect Dis 12: 73-77.
4. Nelson MI, Holmes EC, (2007) The evolution of epidemic influenza. Nat Rev Genet 8: 196-205.
5. Neumann G, Noda T, Kawaoka Y, (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
6. Nistal-Villan E, Garcia-Sastre A, (2009) New prospects for the rational design of antivirals. Nat Med 15: 1253-1254.
7. Das K, Aramini JM, Ma LC, Krug RM, Arnold E, (2010) Structures of influenza A proteins and insights into antiviral drug targets. Nat Strut Mol Biol 17: 530-538.
8. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690.
9. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational Design of Potent Sialidase-Based Inhibitors of Influenza-Virus Replication. Nature 363: 418-423.
10. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, et al. (2000) BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43: 3482-3486.
11. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, et al. (2009) CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity. Antimicrob Agents and Chemother 53: 186-192.
12. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49.
13. von Itzstein M, (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6: 967-974.
14. Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, et al. (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 1: 113.
15. Li Q, Qi JX, Zhang W, Vavricka CJ, Shi Y, et al. (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17: 1266-1268.
16. Amaro RE, Swift RV, Votapka L, Li WW, Walker RC, et al. (2011) Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2: 388.
17. Amaro RE, Minh DD, Cheng LS, Lindstrom WM Jr, Olson AJ, et al. (2007) Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 129: 7764-7765.
18. Wang M, Qi J, Liu Y, Vavricka CJ, Wu Y, et al. (2011) Influenza A virus N5 neuraminidase has an extended 150-cavity. J Virol 85: 8431-8435.
19. Amaro RE, Cheng X, Ivanov I, Xu D, McCammon JA, (2009) Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. J Am Chem Soc 131: 4702-4709.
20. Varghese JN, Colman PM, (1991) 3-Dimensional Structure of the Neuraminidase of Influenza Virus-a/Tokyo/3/67 at 2.2-a Resolution. J Mol Biol 221: 473-486.
21. Mu Y, (2009) Dissociation aided and side chain sampling enhanced Hamiltonian replica exchange. J Chem Phys 130: 164107.
22. Xu W, Lai T, Yang Y, Mu Y, (2008) Reversible folding simulation by hybrid Hamiltonian replica exchange. J Chem Phys 128: 175105.
23. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201.
24. van der Vries E, Collins PJ, Vachieri SG, Xiong XL, Liu JF, et al. (2012) H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis. Plos Pathogens 8: e1002914.
25. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 79: 926-935.
26. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF chimera-A visualization system for exploratory research and analysis. J Computat Chem 25: 1605-1612.
27. Hess B, Kutzner C, van der Spoel D, Lindahl E, (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4: 435-447.
28. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins: Struct Funct and Bioinform 65: 712-725.
29. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM, (1997) LINCS: A linear constraint solver for molecular simulations. J Computat Chem 18: 1463-1472.
30. Darden T, York D, Pedersen L, (1993) Particle Mesh Ewald-an N.Log(N) Method for Ewald Sums in Large Systems. J Chem Phys 98: 10089-10092.
31. Durrant JD, de Oliveira CAF, McCammon JA, (2011) POVME: An algorithm for measuring binding-pocket volumes. J Mol Graph Model 29: 773-776.
32. Christen M, Hunenberger PH, Bakowies D, Baron R, Burgi R, et al. (2005) The GROMOS software for biomolecular simulation: GROMOS05. J Computat Chem 26: 1719-1751.
33. Mu Y, Nguyen PH, Stock G, (2005) Energy landscape of a small peptide revealed by dihedral angle principal component analysis. Proteins: Struct Funct and Bioinform 58: 45-52.
34. Bu Z, Callaway DJE (2011) Chapter 5-Proteins MOVE! Protein dynamics and long-range allostery in cell signaling. In: Rossen D, editor. Advances in Protein Chemistry and Structural Biology: Academic Press. pp. 163-221.
35. Simmerling C, Fox T, Kollman PA, (1998) Use of Locally Enhanced Sampling in Free Energy Calculations: Testing and Application to the α → β Anomerization of Glucose. J Am Chem Soc 120: 5771-5782.
36. Duan S, Boltz DA, Li J, Oshansky CM, Marjuki H, et al. (2011) Novel Genotyping and Quantitative Analysis of Neuraminidase Inhibitor Resistance-Associated Mutations in Influenza A Viruses by Single-Nucleotide Polymorphism Analysis. Antimicrob Agents Chemother 55: 4718-4727.
37. Chachra R, Rizzo RC, (2008) Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations. J Chem Theory Comput 4: 1526-1540.
38. Han N, Liu X, Mu Y, (2012) Exploring the Mechanism of Zanamivir Resistance in a Neuraminidase Mutant: A Molecular Dynamics Study. PLoS ONE 7: e44057.
39. Landon MR, Amaro RE, Baron R, Ngan CH, Ozonoff D, et al. (2008) Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem Biol Drug Des 71: 106-116.
40. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, et al. (2008) Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem 51: 3878-3894.
41. Grienke U, Schmidtke M, Kirchmair J, Pfarr K, Wutzler P, et al. (2010) Antiviral Potential and Molecular Insight into Neuraminidase Inhibiting Diarylheptanoids from Alpinia katsumadai. J Med Chem 53: 778-786.